Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Share-based Compensation (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Share-based Compensation for 4 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 16.11% to $5.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.7 million, a 19.43% increase, with the full-year FY2025 number at $28.7 million, up 19.43% from a year prior.
  • Share-based Compensation was $5.6 million for Q4 2025 at Phathom Pharmaceuticals, down from $9.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $19.3 million in Q4 2023 to a low of $5.5 million in Q1 2025.
  • A 4-year average of $7.3 million and a median of $6.1 million in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 189.92% in 2023, then tumbled 65.35% in 2024.
  • Phathom Pharmaceuticals' Share-based Compensation stood at $6.7 million in 2022, then soared by 189.92% to $19.3 million in 2023, then crashed by 65.35% to $6.7 million in 2024, then dropped by 16.11% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Share-based Compensation are $5.6 million (Q4 2025), $9.3 million (Q3 2025), and $8.3 million (Q2 2025).